FCGR2B and systemic lupus erythematosus: In contrast to some B cell malignancies, B cell expression of FcγRIIb and/or CD20 did not correlate with the in vitro efficiency of mAbs in either RA or SLE, with respect to the target cell expression of FcγRIIb [28, 39] and CD20 [40, 41].